ArticleJournal of medicine and life2025
Management outcomes of prolactinoma: a retrospective study from Southern Iraq.
Article in Journal of medicine and life, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prolactinoma is the most common pituitary adenoma. This study aims to assess the clinical presentation, treatment modalities, and outcomes of patients with prolactinomas and to identify factors that predict remission. We conducted a retrospective single-center study including patients with prolactinoma. Data from medical records were analyzed to correlate patient demographics, clinical presentation, serum prolactin (PRL) levels, and adenoma size on MRI, both at diagnosis and after initiation of dopamine agonist (DA) therapy, with treatment outcomes. A total of 205 patients were included in the study. The mean age of the cohort was 34.8 ± 12.4 years, with a female-to-male ratio of 1.5:1. Oligomenorrhea/amenorrhea was the most common presenting symptom, occurring in 112 of 122 women (91.8%). Macroadenomas accounted for 117 of 176 adenomas (66.4%). Initial treatment consisted of DA therapy in 149 patients, transsphenoidal pituitary surgery in 41 patients, and gamma knife radiosurgery in five patients. A total of 148 patients continued DA therapy at our center. After one year of DA treatment, significant adenoma shrinkage (>30%) was observed in 23 patients (34.3%), while complete adenoma disappearance occurred in six patients (8.9%). At 24 months, 25 of 88 patients (28.4%) achieved remission. Baseline PRL <10,638.2 mIU/L (500 ng/mL) and the presence of microadenoma independently predicted remission. DA therapy remains the cornerstone of prolactinoma treatment in our region and is very effective in normalizing PRL levels, shrinking adenomas, and improving clinical symptoms; DA can be used even in cases of giant prolactinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.